Musculoskeletal disorders (MSDs) affect over 40 million Americans and are the leading cause of activity limitations. Health care costs for arthritis and osteoporosis alone exceed $75 billion per year. In the past decade, there has been a dramatic rise in the number of new therapies for MSDs. During its short tenure, the Alabama Musculoskeletal Disorders CERTs (AMSDC) at the University of Alabama at Birmingham (UAB) has successfully identified, funded and conducted a large number of projects investigating and disseminating knowledge about safe and effective use of MSD therapeutics. Emphasizing the importance of the AMSDC network for promoting multi-disciplinary and public-private programs, the applicant has developed active collaborations with three of the other CERTs, with FDA/CBER and NIAMS, the VAHSR&D, national managed care organizations (Aetna & UHC), CMS' Quality Improvement Organizations (QIOs), the Alabama Department of Public Health and several pharmaceutical manufacturers. These collaborations are indicative of the AMSDC's ability to leverage AHRQ core support to build a productive, diverse, and sustainable center. The application's main objective is to seize the momentum of current successes and continue to expand knowledge regarding MSD therapeutics.
The specific aims of the AMSDC renewal are as follow: 1. Improve safety and effectiveness of musculoskeletal therapeutics through: a. A randomized trial of a combined physician/patient intervention to improve the safety of NSAID uses in the ambulatory setting (Module 1); b. A pharmacoepidemiological study followed by a randomized trial of a direct to patient intervention to improve safety in gout treatment (Supplemental Module 2); c. The support of nine demonstration projects focusing on diverse areas within MSD therapeutics, all bound by the common thread of improving safety and effectiveness, with the goal of submitting applications for funding to outside agencies; 2. Expand existing collaborations in both the private and public healthcare sectors; 3. Educate practitioners, insurers, policy makers, and the general public about musculoskeletal therapeutics. Given the rising burden of MSD in an aging society and the rapidly advancing efficacious, yet costly and potential dangerous, therapeutic options the objective and aims of the AMSDC are both well timed and urgently needed to improve public health.

Agency
National Institute of Health (NIH)
Institute
Agency for Healthcare Research and Quality (AHRQ)
Type
Research Demonstration--Cooperative Agreements (U18)
Project #
2U18HS010389-04
Application #
6780090
Study Section
Special Emphasis Panel (ZHS1-HSR-F (01))
Program Officer
Bosco, Lynn
Project Start
2000-07-01
Project End
2007-09-29
Budget Start
2003-09-30
Budget End
2004-09-29
Support Year
4
Fiscal Year
2003
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Miller, Michael J; Allison, Jeroan J; Cobaugh, Daniel J et al. (2014) A group-randomized trial of shared decision making for non-steroidal anti-inflammatory drug risk awareness: primary results and lessons learned. J Eval Clin Pract 20:638-48
Kilgore, M L; Outman, R; Locher, J L et al. (2013) Multimodal intervention to improve osteoporosis care in home health settings: results from a cluster randomized trial. Osteoporos Int 24:2555-60
Schmitt, Michael R; Miller, Michael J; Harrison, Donald L et al. (2011) Communicating non-steroidal anti-inflammatory drug risks: verbal counseling, written medicine information, and patients' risk awareness. Patient Educ Couns 83:391-7
Pisu, Maria; Crenshaw, Katie; Funkhouser, Ellen et al. (2010) Medication assistance programs: do all in need benefit equally? Ethn Dis 20:339-45
Angner, Erik; Ray, Midge N; Saag, Kenneth G et al. (2009) Health and happiness among older adults: a community-based study. J Health Psychol 14:503-12
Mudano, A S; Bian, J; Cope, J U et al. (2009) Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study. Osteoporos Int 20:819-26
Patkar, Nivedita M; Curtis, Jeffrey R; Teng, Gim Gee et al. (2009) Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol 62:321-7, 327.e1-7
LaCivita, Cynthia; Funkhouser, Ellen; Miller, Michael J et al. (2009) Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007. J Am Pharm Assoc (2003) 49:e110-7
Cobaugh, Daniel J; Angner, Erik; Kiefe, Catarina I et al. (2008) Effect of racial differences on ability to afford prescription medications. Am J Health Syst Pharm 65:2137-43
Kovac, Stacey H; Saag, Kenneth G; Curtis, Jeffrey R et al. (2008) Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugs. Arthritis Rheum 59:227-33

Showing the most recent 10 out of 32 publications